Buprenorphine use while Breastfeeding
Drugs containing Buprenorphine: Suboxone, Butrans, Subutex, Belbuca, Zubsolv, Sublocade, Buprenex, Bunavail, Probuphine
Medically reviewed on May 1, 2018.
Buprenorphine Levels and Effects while Breastfeeding
Summary of Use during Lactation
Because of the low levels of buprenorphine in breastmilk, its poor oral bioavailability in infants, and the low drug concentrations found in the serum and urine of breastfed infants, its use is acceptable in nursing mothers. Monitor the infant for drowsiness, adequate weight gain, and developmental milestones, especially in younger, exclusively breastfed infants. Although unlikely, if the baby shows signs of increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness, a physician should be contacted immediately. Observe infants for withdrawal signs if breastfeeding is stopped abruptly.
Women who received buprenorphine for opiate abuse during pregnancy and are stable should be encouraged to breastfeed their infants postpartum, unless there is another contraindication, such as use of street drugs. The long-term outcome of infants breastfed during maternal buprenorphine therapy for opiate abuse has not been well studied. The breastfeeding rate among mothers taking buprenorphine for opiate dependency may be lower than in other mothers.
Buprenorphine has poor oral bioavailability and is usually given by the sublingual or parenteral route. Sublingual bioavailability is 30 to 40% in adults and peak levels in blood occur 60 to 90 minutes after a dose. Buprenorphine is metabolized to the slightly active metabolite, norbuprenorphine. Further metabolism is by glucuronidation to active metabolites.
Maternal Levels. A breastfeeding mother taking sublingual buprenorphine maintenance 4 mg daily during pregnancy and lactation had milk samples collected 6 times over the course of a day at 4 weeks postpartum. Milk levels and milk volumes ingested by the infant were measured, but not reported. The authors estimated that the total dose ingested by the infant over 1 day was 3.28 mcg of buprenorphine and 0.33 mcg of norbuprenophine. Assuming an infant weight of 4 kg, the infant dosage in this study is equivalent to about 1.4% of the maternal weight-adjusted dosage.
Four mothers who were 4 days postpartum and taking 0.4, 2, 4 or 6 mg of oral buprenorphine maintenance once daily during pregnancy and lactation had their milk collected 2, 4, 6 and 12 hours after a dose. Peak milk levels occurred 2 hours after the dose in the mothers taking 2 and 4 mg and 4 hours after the dose in the mother taking 6 mg daily. Peak levels were 0.8, 7.8 and 5.8 mcg/L, respectively. Milk levels of buprenorphine and norbuprenorphine were undetectable (lower limit of the assay not given) in the mother taking buprenorphine 0.4 mg daily. Average milk levels in the mothers taking 2, 4 and 6 mg were 0.4, 3.5, and 4.4 mcg/L of buprenorphine and 0.57, 0.45, and 1.15 mcg/L of norbuprenorphine, respectively. Based on the average milk levels reported, an exclusively breastfed infant would receive less than 1% of the maternal weight-adjusted dosage. Dosages were on the low end of the usual dosage range for treatment of opiate withdrawal. Furthermore, the authors reported that the mothers' doses were given orally. The oral route is known to have poor bioavailability. The combination of low dose and oral route may have contributed to the low milk levels.
One woman who was receiving daily sublingual buprenorphine (dosage not stated) for narcotic abstinence had milk levels of 520, 720 and 230 ng/L on days 3, 6 and 9 postpartum (times of samples not stated).
One woman who was 8 days postpartum had been receiving buprenorphine 8 mg sublingually for narcotic abstinence for 7 months. Ten random milk samples were collected over 4 days. The highest milk levels of buprenorphine and norbuprenorphine were 14.7 and 6.3 mcg/L. Using the peak milk level data, the estimated maximum intake of an exclusively breastfed infant would be 2.4% of the maternal weight-adjusted dosage of buprenorphine and norbuprenorphine, but not including the contribution of any glucuronide metabolite.
Six women receiving a median daily dose of 0.29 mg/kg of buprenorphine sublingually for opiate abstinence were studied during the first 5 to 8 days postpartum. Hindmilk samples were obtained 6 to 8 times over a 24-hour period. Breastmilk contained estimated median infant doses of 0.42 mcg/kg of buprenorphine and 0.33 mcg/kg of norbuprenorphine daily, which are equivalent to 0.2% and 0.12% of the maternal weight-adjusted dosage. The range of buprenorphine plus norbuprenorphine was 0.18% to 0.77% of the maternal weight-adjusted dosage. Milk from the nursing mother of a 9-month-old infant receiving 0.32 mg/kg of buprenorphine had concentrations of the drug and metabolite similar to those of the other women.
Seven infant who averaged 1.12 months postpartum (range 0.58 to 1.85 months) and taking buprenorphine sublingually for opiate substitution during pregnancy and lactation collected foremilk and hindmilk samples with each feeding for 24 hours. The average maternal dosage was 9.3 mg daily and the median was 7 mg daily (range 2.4 to 24 mg daily). The average buprenorphine concentration in milk was 3.65 mcg/L and the average norbuprenorphine concentration was 1.94 mcg/L. These corresponded to daily dosages of 0.55 and 0.29 mcg/kg, respectively and weight-adjusted dosages of 0.38% and 0.18% of the maternal dosage, respectively.
One woman taking sublingual buprenorphine in an unstated dosage donated breastmilk samples on 5 occasions over a 30-day period. Buprenorphine concentrations ranged from 2.4 to 4 mcg/L, buprenorphine glucuronide 0.8 to 9.3 mcg/L, norbuprenorphine 3.2 to 4.0 mcg/L, and norbuprenorphine glucuronide 24.9 to 34.5 mcg/L.
Ten women on buprenorphine maintenance therapy with sublingual dosages ranging from 2 to 22 mg once daily. Milk samples were provided 2 to 2.5 hours after the daily dose on days 2, 3, 4, 14, and 30 postpartum. Median buprenorphine milk levels ranged from 1.4 to 4.8 mcg/L, median norbuprenorphine milk levels ranged from 0.1 to 0.2 mcg/L, median buprenorphine glucuronide milk levels ranged from 2.3 to 3.2 mcg/L, and median norbuprenorphine glucuronide milk levels ranged from 0.4 to 1.8 mcg/L. Concentrations in milk were positively correlated to the maternal dose.
Infant Levels. Six nursing infants from 5 to 8 days of age whose mothers were taking a median daily dose of 0.29 mg/kg of buprenorphine sublingually had one urine sample collected between 4 and 20 hours after the previous maternal dose. Buprenorphine was undetectable (<187 ng/L) in 3 infants; the other 3 had urine concentrations of about 468 ng/L. Norbuprenorphine urine concentrations ranged from 414 to 1987 ng/L (median 952 ng/L). A seventh 9-month-old breastfed infant whose mother was taking 20 mg (0.32 mg/kg) of buprenorphine daily had serum and urine collected. Serum concentrations of buprenorphine and norbuprenorphine were 234 ng/L and 745 ng/L, respectively, at 2.25 hours after the previous maternal dose. A urine sample obtained 3.5 hours after the previous maternal dose contained <234 ng/L and 455 ng/L of the drug and metabolite, respectively.
The infant of a mother receiving buprenorphine (dosage not stated) was breastfeeding (extent not stated). A single blood sample from the infant after 14 days of maternal sublingual buprenorphine use contained 0.7 mcg/L of buprenorphine. No buprenorphine metabolites were detected.
Nine infants were breastfed (3 exclusively and 6 partially) by mothers who were taking sublingual buprenorphine in single daily doses ranging from 2 to 22 mg once daily. A blood sample from a heel stick was taken on day 14 postpartum. Doses of the individual mothers and the time since the last dose and time since the last breastfeeding were not stated. Buprenorphine was detectable (>0.1 mcg/L) in the plasma of only 4 of the infants, with the highest reported plasma level of 2.9 mcg/L. Norbuprenorphine (<2 mcg/L) and the glucuronide metabolites of buprenorphine (<0.1 mcg/L) and norbuprenorphine (<0.25) were not detectable in any of the infants.
Effects in Breastfed Infants
Numerous infants have been reported to breastfeed during maternal narcotic abstinence therapy with buprenorphine with no adverse effects, one for 6 months. The amounts of buprenorphine in milk may not be sufficient to prevent neonatal withdrawal, and treatment of infant may be required.
Despite breastfeeding and relatively high infant serum drug levels, mild buprenorphine withdrawal occurred in the neonate of a mother taking buprenorphine 4 mg daily (route not specified) during pregnancy and postpartum for heroin dependency. This indicates that an insufficient dosage appeared in milk to prevent neonatal abstinence.
Ten women who had undergone cesarean section delivery of term newborns were given extradural buprenorphine 200 mcg followed by 8.4 mcg/hour with an anesthetic for postoperative pain for 3 days postpartum. A control group of 10 other women were given extradural anaesthetic only without buprenorphine. Over 11 days postpartum, newborns of mothers in the buprenorphine group had much lower milk intake and lower weight gain than those in the non-buprenorphine group. The authors suggested that extradural buprenorphine suppressed infant breastfeeding. Infant neurobehavioral assessments were not performed.
Six infants whose mothers were taking buprenorphine during pregnancy and postpartum were breastfed. Four of the infants had signs of opioid abstinence, indicating that the amounts of buprenorphine in breastmilk were inadequate to prevent withdrawal. At 1 month after discharge from the hospital, all infants had normal development and weight gain.
Seven infant who averaged 1.12 months of age (range 0.58 to 1.85 months) were being breastfed by mothers taking buprenorphine for opiate substitution during pregnancy and lactation. Urine screening indicated that 4 mothers had also been using cannabis, 1 was using unprescribed benzodiazepines, and 1 mother was using both cannabis and benzodiazepines. Four of the infants were exclusively breastfed and 3 were mostly breastfed. Infants had no apparent drug-related adverse effects and showed satisfactory developmental progress.
A mother used buprenorphine (dose and indication not stated) during pregnancy. Her infant displayed no signs of neonatal abstinence at birth. The infant was breastfed (extent not stated) until 4 months of age when the mother stopped breastfeeding. Two days later the infant had withdrawal symptoms including frequent yawning, sneezing, pupillary dilation, agitation, sweating, hyperactive Moro reflex, myoclonic jerks, tremors, and insomnia. The infant was given methadone with immediate improvement of her withdrawal symptoms. The infant's withdrawal symptoms were probably caused by abrupt withdrawal of breastfeeding.
In a study of 7 women taking buprenorphine in a median dose of 7 mg daily (range 2.4 to 24 mg daily) , breastfed infants were followed-up at 3 and 4 weeks of age. Four infants were exclusively breastfed and 3 were partially breastfed. At the follow-up visits, infants were assessed for weight gain, sleeping patterns, skin color, and elimination and hydration patterns. All infants had values within normal limits for these parameters at follow-up.
A cohort of 124 infants exposed during pregnancy to maternal medication for opioid maintenance therapy were followed postpartum in a Norwegian study. Forty-six infants were born to mothers taking buprenorphine. Overall, infants who were breastfed had a lower rate of neonatal abstinence symptoms and a shorter duration of therapy for neonatal abstinence. However, the differences were not statistically significant for the subset of infants whose mothers took buprenorphine.
A study of pregnant women being treated for opiate dependency with buprenorphine at a clinic in Vienna were followed as were their newborn infants. No difference was found between breastfed (n = 31) and nonbreastfed infant (n = 41) in average measures of neonatal abstinence, dosage requirements of morphine, durations of treatment for neonatal abstinence or durations of hospital stays.
Effects on Lactation and Breastmilk
Buprenorphine can increase serum prolactin. However, the prolactin level in a mother with established lactation may not affect her ability to breastfeed.
In a multicenter prospective study of 246 pregnant women receiving either methadone or buprenorphine for opiate dependency, 153 women were receiving high-dose buprenorphine. Twenty-two percent of women receiving buprenorphine breastfed their infants, which was the same percentage as those receiving methadone.
A case series of opiate-dependent mothers who delivered in a Baby Friendly Hospital found that mothers taking buprenorphine or methadone for opiate dependency were unlikely to breastfeed their infants. Only 45% of the 20 mothers on buprenorphine maintenance initiated breastfeeding. Of all women in the study, 60% discontinued breastfeeding before discharge from the hospital.
A retrospective case series reported on 85 opioid-dependent women maintained on buprenorphine during pregnancy and postpartum during the period of December 2007 to August 2012. Of these women, 65 were breastfeeding on discharge from the hospital and 66% of these were breastfeeding at their 6- to 8-week follow-up appointment (extent of nursing not stated).
A retrospective cohort study in Australia compared breastfeeding rates on discharge of drug-using mothers who were taking either buprenorphine, other opiates or nonopiates (e.g., benzodiazepines, amphetamines, cocaine, alcohol, inhalants, cannabinoids, psychotropics). Breastfeeding rates at discharge from the hospital were as follows: buprenorphine 27%, other opiates 31%, and nonopiates 51%.
A small retrospective study found that only 3 of 10 pregnant women treated with buprenorphine plus naloxone for opioid dependence were breastfeeding their infants at the time of hospital discharge.
Alternate Drugs to Consider
1. Kocherlakota P. Neonatal abstinence syndrome. Pediatrics. 2014;134:e547-e561. PMID: 25070299
2. Sutter MB, Leeman L, Hsi A. Neonatal opioid withdrawal syndrome. Obstet Gynecol Clin North Am. 2014;41:317-34. PMID: 24845493
3. Mozurkewich EL, Rayburn WF. Buprenorphine and methadone for opioid addiction during pregnancy. Obstet Gynecol Clin North Am. 2014;41:241-53. PMID: 24845488
4. Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract. 2014;9:19. PMID: 25199822
5. Lefevere J, Allegaert K. Question: Is breastfeeding useful in the management of neonatal abstinence syndrome? Arch Dis Child. 2015;100:414-5. PMID: 25784740
6. Reece-Stremtan S, Marinelli KA. ABM Clinical Protocol #21: Guidelines for Breastfeeding and Substance Use or Substance Use Disorder, Revised 2015. Breastfeed Med. 2015;10:135-41. PMID: 25836677
7. Cleveland LM. Breastfeeding recommendations for women who receive medication-assisted treatment for opioid use disorders: AWHONN Practice Brief Number 4. Nurs Womens Health. 2016;20:432-4. PMID: 27520608
8. McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med. 2016;375:2468-79. PMID: 28002715
9. Holmes AP, Schmidlin HN, Kurzum EN. Breastfeeding considerations for mothers of infants with neonatal abstinence syndrome. Pharmacotherapy. 2017;37:861-9. PMID: 28488805
10. Mascola MA, Borders AE, Terplan M. Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017;130:e81-e94. PMID: 28742676
11. Wachman EM, Schiff DM, Silverstein M. Neonatal abstinence syndrome: Advances in diagnosis and treatment. JAMA. 2018;319:1362-74. PMID: 29614184
12. Marquet P, Chevrel J, Lavignasse P et al. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther. 1997;62:569-71. PMID: 9390114
13. Jernite M, Diemunsch P, Kintz P. Buprenorphine excretion in breast milk. Anesthesiology. 1999;91:A1095. Abstract.
14. Jernite M, Diemunsch P, Kintz P et al. [Passage of buprenorphine into mother's milk]. Ann Fr Anesth Reanim. 1999;18 (Suppl 1):109S. Abstract.
15. Johnson RE, Jones HE, Jasinski DR et al. Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes. Drug Alcohol Depend. 2001;63:97-103. PMID: 11297835
16. Grimm D, Pauly E, Poschl J et al. Buprenorphine and norbuprenorphine concentrations in human breast milk samples determined by liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2005;27:526-30. PMID: 16044112
17. Lindemalm S, Nydert P, Svensson JO et al. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact. 2009;25:199-205. PMID: 19136395
18. Ilett KF, Hackett LP, Gower S et al. Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. Breastfeed Med. 2012;7:269-74. PMID: 22011128
19. Swortwood MJ, Scheidweiler KB, Barnes AJ et al. Simultaneous quantification of buprenorphine, naloxone and phase I and II metabolites in plasma and breastmilk by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2016;1446:70-7. PMID: 27083254
20. Jansson LM, Spencer N, McConnell K et al. Maternal buprenorphine maintenance and lactation. J Hum Lact. 2016;32:675-81. PMID: 27563013
21. Schindler SD, Eder H, Ortner R et al. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction. 2003;98:103-10. PMID: 12492761
22. Kayemba-Kay's S, Laclyde JP. Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. Addiction. 2003;98:1599-604. PMID: 14616186
23. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003;70 (2 Suppl):S87-S101. PMID: 12738353
24. Loustauneau A, Auriacombe M, Daulouede JP, Tignol J. [Is buprenorphine a potential alternative to methadone for treating pregnant drug users? Inventory of clinical data in the literature]. Ann Med Interne (Paris). 2002;153 (7 Suppl):2S31-6. PMID: 12518080
25. Hirose M, Hosokawa T, Tanaka Y. Extradural buprenorphine suppresses breast feeding after cesarean section. Br J Anaesth. 1997;79:120-1. PMID: 9301399
26. Elladki H, Thill P. Buprenorphine withdrawal in an infant after cessation of breastfeeding: A case report and review of the literature. Pharmacotherapy. 2011;31:435e. Abstract.
27. Gower S, Bartu A, Ilett KF et al. The wellbeing of infants exposed to buprenorphine via breast milk at 4 weeks of age. J Hum Lact. 2014;30:217-23. PMID: 24399105
28. Welle-Strand GK, Skurtveit S, Jansson LM et al. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr. 2014;102:1060-6. PMID: 23909865
29. Metz VE, Comer SD, Pribasnig A et al. Observational study in an outpatient clinic specializing in treating opioid-dependent pregnant women: Neonatal abstinence syndrome in infants exposed to methadone-, buprenorphine- and slow-release oral morphine. Heroin Addict Relat Clin Probl. 2015;17:5-15.
30. Saarialho-Kere U, Mattila MJ, Paloheimo M, Seppala T. Psychomotor, respiratory and neuroendocrinological effects of buprenorphine and amitriptyline in healthy volunteers. Eur J Clin Pharmacol. 1987;33:139-46. PMID: 3691607
31. Lejeune C, Aubisson S, Simmat-Durand L et al. [Withdrawal syndromes of newborns of pregnant drug abusers maintained under methadone or high-dose buprenorphine: 246 cases]. Ann Med Interne (Paris). 2001;152 (Suppl 7):21-7. PMID: 11965095
32. Wachman EM, Byun J, Philipp BL. Breastfeeding rates among mothers of infants with neonatal abstinence syndrome. Breastfeed Med. 2010;5:159-64. PMID: 20658895
33. O'Connor AB, Collett A, Alto WA, O'Brien LM. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. J Midwifery Womens Health. 2013;58:383-8. PMID: 23931660
34. Patel P, Abdel-Latif ME, Hazelton B et al. Perinatal outcomes of Australian buprenorphine-exposed mothers and their newborn infants. J Paediatr Child Health. 2013;49:746-53. PMID: 23745982
35. Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict. 2013;22:252-4. PMID: 23617867
CAS Registry Number
LactMed Record Number
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about buprenorphine
- Buprenorphine Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- 405 Reviews – Add your own review/rating
- Drug class: narcotic analgesics
- Buprenorphine implant
- Buprenorphine injection - Buprenex
- Buprenorphine injection - Sublocade
- Buprenorphine oral/buccal
- Buprenorphine oral/sublingual
- ... +10 more